相关实验视频

Updated: Jul 5, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

网络对转移性清细胞细胞癌的第二线和超越治疗选择的元分析

Mavis Obeng-Kusi¹, Jordyn J Kreutzfeldt², Ricardo J Estrada-Mendizabal³

¹Center for Health Outcomes and Pharmacoeconomic Research, Department of Pharmacy Practice and Science, University of Arizona R. Ken Coit College of Pharmacy, Tucson, AZ.

Urologic oncology

|January 12, 2024

概括

伦瓦提尼布加Everolimus显示,转移性清洁细胞癌的整体存活率和无进展存活率优越. 然而,与安慰剂相比,这种组合和其他有效治疗与严重不良事件的增加有关.

科学领域:

在瘤学瘤学.
医学研究医学研究
药理学药理学是指药理学的学科.

背景情况:

对转移性清细胞细胞癌 (ccRCC) 进行最佳的二线 (2L) 治疗选择是复杂的.
对于可用的2L疗法存在有限的比较数据,特别是考虑到不断发展的第一线 (1L) 选择.

研究的目的:

进行网络元分析 (NMA),比较转移性ccRCC的二线治疗方法.
评估各种2L疗法的整体存活率 (OS),无进展存活率 (PFS),客观反应率 (ORR) 和严重不良事件 (SAE).

主要方法:

对2L转移性ccRCC治疗的II/III期随机对照试验 (RCT) 的系统识别.
网络元分析使用正常概率模型来比较包括OS,PFS,ORR和SAE在内的结果.
在固定效应模型中,根据从危险比率 (HR) 和赔率比率 (OR) 获得的p-score来对治疗进行排名.

主要成果:

与安慰剂相比,伦瓦提尼布加Everolimus在OS,PFS和ORR方面表现出更高的疗效,但SAE增加.
卡博桑提尼布在OS,PFS和ORR方面显示出第二好的结果.
尼沃卢马布和帕佐帕尼布的严重不良事件发生率最低,而伦瓦提尼布单一治疗与最高的SAE相关.

结论:

伦瓦提尼布加Everolimus的组合,其次是卡博赞提尼布和伦瓦提尼布单一治疗,提供了优越的OS和PFS.
所有有效的治疗都与严重不良事件的风险增加有关.
尼沃卢马布和帕佐帕尼布在严重不良事件方面呈现了最有利的安全概况.

关键词:

免疫检查点抑制剂免疫检查点抑制剂网络元分析网络元分析目标响应率目标响应率总体生存率总体生存率没有进展的生存率.耐火的耐火的耐火的复发复发的情况细胞癌是细胞癌.第二线的第二线.严重的不良事件严重的不良事件铁氨酸激酶抑制剂铁氨酸激酶抑制剂治疗治疗治疗治疗治疗治疗

更多相关视频

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...